Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects

Phase 1

Completed

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: Z0063
Drug: Gaviscon

First Posted Date: 2017-02-28

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 34

Registration Number: NCT03065816

Locations: 🇬🇧
Investigational site 826001, Merthyr Tydfil, United Kingdom

Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Sotagliflozin (SAR439954)
Drug: Rifampicin

First Posted Date: 2017-02-24

Last Posted Date: 2022-04-25

Lead Sponsor: Sanofi

Target Recruit Count: 16

Registration Number: NCT03063580

Locations: 🇫🇷
Investigational Site Number 250001, Gieres, France

Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China

Phase 3

Completed

Conditions: Hyperphosphatemia

Interventions: Drug: Sevelamer Carbonate (GZ419831)
Drug: Placebo

First Posted Date: 2016-12-22

Last Posted Date: 2022-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 202

Registration Number: NCT03001011

Locations: 🇨🇳
Investigational Site Number 1560001, Guangzhou, China
🇨🇳
Investigational Site Number 1560003, Beijing, China
🇨🇳
Investigational Site Number 1560015, Changchun, China

and more 35 locations

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Phase 2

Terminated

Conditions: T-lymphoblastic Lymphoma/Leukaemia
T-cell Type Acute Leukemia-Precursor

Interventions: Drug: Isatuximab SAR650984
Drug: dexamethasone
Drug: acetaminophen
Drug: ranitidine
Drug: diphenhydramine

First Posted Date: 2016-12-21

Last Posted Date: 2022-03-21

Lead Sponsor: Sanofi

Target Recruit Count: 14

Registration Number: NCT02999633

Locations: 🇺🇸
Investigational Site Number 8400001, Houston, Texas, United States
🇺🇸
Investigational Site Number 8400002, Atlanta, Georgia, United States
🇫🇮
Investigational Site Number 2460001, Helsinki, Finland

and more 14 locations

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

Phase 3

Completed

Conditions: Plasma Cell Myeloma

Interventions: Drug: Pomalidomide
Drug: Isatuximab
Drug: Dexamethasone

First Posted Date: 2016-12-13

Last Posted Date: 2025-01-17

Lead Sponsor: Sanofi

Target Recruit Count: 307

Registration Number: NCT02990338

Locations: 🇺🇸
BRCR Medical Center Inc. Site Number : 8400002, Plantation, Florida, United States
🇺🇸
Dana Farber Site Number : 8400006, Boston, Massachusetts, United States
🇦🇺
Investigational Site Number : 0360004, St Leonards, New South Wales, Australia

and more 108 locations

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Phase 2

Recruiting

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Sarilumab SAR153191 (REGN88)

First Posted Date: 2016-12-13

Last Posted Date: 2025-04-23

Lead Sponsor: Sanofi

Target Recruit Count: 72

Registration Number: NCT02991469

Locations: 🇦🇷
Investigational Site Number : 0320004, San Miguel de Tucumán, Tucumán, Argentina
🇧🇬
Investigational Site Number : 1000001, Plovdiv, Bulgaria
🇨🇦
Investigational Site Number : 1240110, Calgary, Alberta, Canada

and more 24 locations

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

Phase 4

Completed

Conditions: Hypercholesterolemia
Acute Coronary Syndrome

Interventions: Drug: Alirocumab SAR236553
Drug: Atorvastatin
Drug: Fenofibrate
Drug: Rosuvastatin
Drug: Bezafibrate
Drug: Ezetimibe
Drug: Antiplatelets
Drug: Anticoagulants

First Posted Date: 2016-12-07

Last Posted Date: 2019-09-09

Lead Sponsor: Sanofi

Target Recruit Count: 206

Registration Number: NCT02984982

Locations: 🇯🇵
Investigational Site Number 392008, Gifu-shi, Japan
🇯🇵
Investigational Site Number 392022, Chiyoda-ku, Japan
🇯🇵
Investigational Site Number 392039, Hiroshima-shi, Japan

and more 36 locations

Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer

Phase 2

Terminated

Conditions: Triple Negative Breast Cancer

Interventions: Drug: SAR566658 (ACT14884)

First Posted Date: 2016-12-07

Last Posted Date: 2021-09-08

Lead Sponsor: Sanofi

Target Recruit Count: 23

Registration Number: NCT02984683

Locations: 🇳🇱
Investigational Site Number 5280002, Rotterdam, Netherlands
🇧🇪
Investigational Site Number 0560001, Leuven, Belgium
🇨🇿
Investigational Site Number 2030002, Praha 2, Czechia

and more 10 locations